(PBH) Prestige Brand Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US74112D1019
Stock: Pain Relief, Baby Care, Throat Care, Eye Care, Skin Care
Total Rating 33
Risk 83
Buy Signal -0.43
| Risk 5d forecast | |
|---|---|
| Volatility | 23.8% |
| Relative Tail Risk | -3.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.08 |
| Alpha | -29.33 |
| Character TTM | |
|---|---|
| Beta | 0.305 |
| Beta Downside | 1.249 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.49% |
| CAGR/Max DD | 0.12 |
EPS (Earnings per Share)
Revenue
Description: PBH Prestige Brand Holdings March 04, 2026
Prestige Consumer Healthcare Inc. (PBH) develops, manufactures, and distributes over-the-counter (OTC) health and personal care products globally. The company operates in two segments: North American OTC Healthcare and International OTC Healthcare.
PBHs product portfolio includes established brands across various categories. These include pain relief (BC, Goodys), baby care (Boudreauxs Butt Paste), sore throat relief (Chloraseptic), eye care (Clear Eyes), wart removal (Compound W), and ear wax removal (Debrox). The OTC healthcare market is characterized by consistent consumer demand for self-care solutions.
Additional brands cover dental care (DenTek), motion sickness (Dramamine), digestive health (Fleet, Gaviscon), cough relief (Ludens), feminine care (Monistat, Summers Eve), lice treatment (Nix), dry eye relief (TheraTears), nasal care (Fess), and oral rehydration (Hydralyte). The consumer staples sector, which includes OTC healthcare, typically exhibits defensive characteristics during economic downturns.
Distribution channels include mass merchandisers, drugstores, food stores, dollar stores, convenience stores, club stores, and e-commerce platforms. The company was founded in 1996 and is headquartered in Tarrytown, New York. For more in-depth analysis, consider exploring ValueRays comprehensive reports.
Headlines to watch out for
- OTC healthcare product sales drive North American revenue growth
- International expansion boosts sales in new markets
- Raw material costs impact profit margins
- Consumer spending trends influence discretionary health product purchases
- Regulatory changes for OTC products create compliance risks
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 186.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.18 > 1.0 |
| NWC/Revenue: 26.62% < 20% (prev 24.56%; Δ 2.06% < -1%) |
| CFO/TA 0.08 > 3% & CFO 276.6m > Net Income 186.5m |
| Net Debt (1.02b) to EBITDA (338.5m): 3.00 < 3 |
| Current Ratio: 3.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.1m) vs 12m ago -3.81% < -2% |
| Gross Margin: 56.38% > 18% (prev 0.55%; Δ 5582 % > 0.5%) |
| Asset Turnover: 32.35% > 50% (prev 33.58%; Δ -1.23% > 0%) |
| Interest Coverage Ratio: 7.40 > 6 (EBITDA TTM 338.5m / Interest Expense TTM 41.7m) |
Altman Z'' 3.79
| A: 0.08 (Total Current Assets 433.4m - Total Current Liabilities 139.6m) / Total Assets 3.49b |
| B: 0.48 (Retained Earnings 1.69b / Total Assets 3.49b) |
| C: 0.09 (EBIT TTM 308.4m / Avg Total Assets 3.41b) |
| D: 1.00 (Book Value of Equity 1.66b / Total Liabilities 1.67b) |
| Altman-Z'' Score: 3.79 = AA |
Beneish M -2.98
| DSRI: 1.15 (Receivables 190.5m/167.3m, Revenue 1.10b/1.12b) |
| GMI: 0.98 (GM 56.38% / 55.12%) |
| AQI: 0.97 (AQ_t 0.83 / AQ_t-1 0.85) |
| SGI: 0.99 (Revenue 1.10b / 1.12b) |
| TATA: -0.03 (NI 186.5m - CFO 276.6m) / TA 3.49b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of PBH shares?
As of March 09, 2026, the stock is trading at USD 67.19 with a total of 405,273 shares traded.
Over the past week, the price has changed by -1.96%, over one month by +2.82%, over three months by +11.41% and over the past year by -22.65%.
Over the past week, the price has changed by -1.96%, over one month by +2.82%, over three months by +11.41% and over the past year by -22.65%.
Is PBH a buy, sell or hold?
Prestige Brand Holdings has received a consensus analysts rating of 3.71.
Therefor, it is recommend to hold PBH.
- StrongBuy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the PBH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 77.8 | 15.8% |
| Analysts Target Price | 77.8 | 15.8% |
PBH Fundamental Data Overview March 05, 2026
P/E Trailing = 18.2058
P/E Forward = 14.3885
P/S = 3.0063
P/B = 1.7725
P/EG = 2.2149
Revenue TTM = 1.10b USD
EBIT TTM = 308.4m USD
EBITDA TTM = 338.5m USD
Long Term Debt = 1.03b USD (from longTermDebt, last quarter)
Short Term Debt = 8.63m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.02b USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (3.32b + Debt 1.08b - CCE 62.4m)
Interest Coverage Ratio = 7.40 (Ebit TTM 308.4m / Interest Expense TTM 41.7m)
EV/FCF = 16.22x (Enterprise Value 4.33b / FCF TTM 267.2m)
FCF Yield = 6.16% (FCF TTM 267.2m / Enterprise Value 4.33b)
FCF Margin = 24.21% (FCF TTM 267.2m / Revenue TTM 1.10b)
Net Margin = 16.90% (Net Income TTM 186.5m / Revenue TTM 1.10b)
Gross Margin = 56.38% ((Revenue TTM 1.10b - Cost of Revenue TTM 481.5m) / Revenue TTM)
Gross Margin QoQ = 55.52% (prev 56.21%)
Tobins Q-Ratio = 1.24 (Enterprise Value 4.33b / Total Assets 3.49b)
Interest Expense / Debt = 0.99% (Interest Expense 10.7m / Debt 1.08b)
Taxrate = 24.46% (15.1m / 61.8m)
NOPAT = 232.9m (EBIT 308.4m * (1 - 24.46%))
Current Ratio = 3.11 (Total Current Assets 433.4m / Total Current Liabilities 139.6m)
Debt / Equity = 0.59 (Debt 1.08b / totalStockholderEquity, last quarter 1.83b)
Debt / EBITDA = 3.00 (Net Debt 1.02b / EBITDA 338.5m)
Debt / FCF = 3.81 (Net Debt 1.02b / FCF TTM 267.2m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.47% (Net Income 186.5m / Total Assets 3.49b)
RoE = 10.16% (Net Income TTM 186.5m / Total Stockholder Equity 1.84b)
RoCE = 10.74% (EBIT 308.4m / Capital Employed (Equity 1.84b + L.T.Debt 1.03b))
RoIC = 8.20% (NOPAT 232.9m / Invested Capital 2.84b)
WACC = 5.50% (E(3.32b)/V(4.40b) * Re(7.04%) + D(1.08b)/V(4.40b) * Rd(0.99%) * (1-Tc(0.24)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.05%
[DCF] Terminal Value 86.78% ; FCFF base≈259.8m ; Y1≈272.0m ; Y5≈315.6m
[DCF] Fair Price = 176.4 (EV 9.36b - Net Debt 1.02b = Equity 8.35b / Shares 47.3m; r=5.90% [WACC]; 5y FCF grow 5.04% → 2.90% )
EPS Correlation: 21.12 | EPS CAGR: 6.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -4.30 | Revenue CAGR: 1.61% | SUE: -0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.01 | Chg7d=+0.007 | Chg30d=+0.007 | Revisions Net=-1 | Analysts=3
EPS next Year (2027-03-31): EPS=4.80 | Chg7d=-0.026 | Chg30d=-0.035 | Revisions Net=-3 | Growth EPS=+5.7% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 7.9% - Earnings Yield 5.5%)
[Growth] Growth Spread = +0.4% (Analyst 2.8% - Implied 2.5%)
P/E Forward = 14.3885
P/S = 3.0063
P/B = 1.7725
P/EG = 2.2149
Revenue TTM = 1.10b USD
EBIT TTM = 308.4m USD
EBITDA TTM = 338.5m USD
Long Term Debt = 1.03b USD (from longTermDebt, last quarter)
Short Term Debt = 8.63m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.02b USD (from netDebt column, last quarter)
Enterprise Value = 4.33b USD (3.32b + Debt 1.08b - CCE 62.4m)
Interest Coverage Ratio = 7.40 (Ebit TTM 308.4m / Interest Expense TTM 41.7m)
EV/FCF = 16.22x (Enterprise Value 4.33b / FCF TTM 267.2m)
FCF Yield = 6.16% (FCF TTM 267.2m / Enterprise Value 4.33b)
FCF Margin = 24.21% (FCF TTM 267.2m / Revenue TTM 1.10b)
Net Margin = 16.90% (Net Income TTM 186.5m / Revenue TTM 1.10b)
Gross Margin = 56.38% ((Revenue TTM 1.10b - Cost of Revenue TTM 481.5m) / Revenue TTM)
Gross Margin QoQ = 55.52% (prev 56.21%)
Tobins Q-Ratio = 1.24 (Enterprise Value 4.33b / Total Assets 3.49b)
Interest Expense / Debt = 0.99% (Interest Expense 10.7m / Debt 1.08b)
Taxrate = 24.46% (15.1m / 61.8m)
NOPAT = 232.9m (EBIT 308.4m * (1 - 24.46%))
Current Ratio = 3.11 (Total Current Assets 433.4m / Total Current Liabilities 139.6m)
Debt / Equity = 0.59 (Debt 1.08b / totalStockholderEquity, last quarter 1.83b)
Debt / EBITDA = 3.00 (Net Debt 1.02b / EBITDA 338.5m)
Debt / FCF = 3.81 (Net Debt 1.02b / FCF TTM 267.2m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.47% (Net Income 186.5m / Total Assets 3.49b)
RoE = 10.16% (Net Income TTM 186.5m / Total Stockholder Equity 1.84b)
RoCE = 10.74% (EBIT 308.4m / Capital Employed (Equity 1.84b + L.T.Debt 1.03b))
RoIC = 8.20% (NOPAT 232.9m / Invested Capital 2.84b)
WACC = 5.50% (E(3.32b)/V(4.40b) * Re(7.04%) + D(1.08b)/V(4.40b) * Rd(0.99%) * (1-Tc(0.24)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.05%
[DCF] Terminal Value 86.78% ; FCFF base≈259.8m ; Y1≈272.0m ; Y5≈315.6m
[DCF] Fair Price = 176.4 (EV 9.36b - Net Debt 1.02b = Equity 8.35b / Shares 47.3m; r=5.90% [WACC]; 5y FCF grow 5.04% → 2.90% )
EPS Correlation: 21.12 | EPS CAGR: 6.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -4.30 | Revenue CAGR: 1.61% | SUE: -0.34 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.01 | Chg7d=+0.007 | Chg30d=+0.007 | Revisions Net=-1 | Analysts=3
EPS next Year (2027-03-31): EPS=4.80 | Chg7d=-0.026 | Chg30d=-0.035 | Revisions Net=-3 | Growth EPS=+5.7% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 7.9% - Earnings Yield 5.5%)
[Growth] Growth Spread = +0.4% (Analyst 2.8% - Implied 2.5%)